Ophthalmology

Boehringer Ingelheim and Inflammasome Therapeutics Inc. have announced that they have entered into a definitive a co-development and license agreement to develop therapies for the patients with retinal diseases.The deal is about jointly developing three novel therapies for retinal diseases with the help of Inflammasome’s unique intravitreal (IVT) drug delivery technologies along with Boehringer Ingelheim’s compounds. Boehringer Ingelheim is advancing its pipeline in retinal disease explicitly focusing on patients with wet Age-related Macular Degeneration (wAMD), Geographic Atrophy, Diabetic Retinopathy, Diabetic Macular Ischemia, Stargardt disease and other related...